SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes
Primary Purpose
Hypoxia, High Altitude
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
SJOV
HFNO
Sponsored by
About this trial
This is an interventional prevention trial for Hypoxia
Eligibility Criteria
Inclusion Criteria:
- 18 years or older;
- underwent routine gastrointestinal endoscopy under procedural sedation;
- consented to participate in this trial.
Exclusion Criteria:
- infection of the upper airway;
- anatomical abnormalities of the face, nose, and upper airway;
- coagulopathies;
- anticipated or known difficult airway;
- known allergy against propofol, soybeans, and egg;
- absence from the high-altitude environment during the past 3 months.
Sites / Locations
- Tibet autonomous region people's hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Supraglottic jet oxygenation and ventilation
High-flow nasal oxygen therapy
Arm Description
Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
High-flow nasal oxygen therapy is conducted for the participants during sedation.
Outcomes
Primary Outcome Measures
Hypoxia during sedation
An SPO2 of 75 - 89% for < 60 s
Secondary Outcome Measures
respiratory-related complications
pulmonary aspiration, respiratory depression (SPO2 = 90-95%) and severe hypoxia (SPO2 < 75% or < 90% for > 60s)
cardiovascular-related complications
hypotension (systolic blood pressure < 90 mmHg), hypertension (systolic blood pressure > 160 mmHg), bradycardia (heart rate < 50 beats/min), tachycardia (heart rate > 120 beats/min)
fatal complications
severe anaphylactic reactions, myocardial infarction, cardiac arrest and death
Full Information
NCT ID
NCT05474287
First Posted
July 22, 2022
Last Updated
October 13, 2022
Sponsor
Peking University People's Hospital
Collaborators
Tibet Autonomous Region People's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05474287
Brief Title
SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes
Official Title
Hypoxemia During Deep Sedation for Gastrointestinal Endoscopy at High Altitudes: High-flow Nasal Oxygen Therapy vs. Supraglottic Jet Oxygenation and Ventilation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 14, 2022 (Actual)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
February 28, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University People's Hospital
Collaborators
Tibet Autonomous Region People's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study aims to compare the effect of the use of supraglottic jet oxygenation and ventilation (SJOV) with high-flow nasal oxygen therapy (HFNO) on reducing the rate of hypoxia during gastrointestinal endoscopic procedures in deeply sedated patients at high altitudes.
Detailed Description
The participants will be randomly allocated to either SJOV or HFNO in a 1:1 ratio using block randomization with variable block sizes of four or six randomized. In the HFNO group, oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%. In the SJOV group, SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoxia, High Altitude
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
72 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Supraglottic jet oxygenation and ventilation
Arm Type
Experimental
Arm Description
Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
Arm Title
High-flow nasal oxygen therapy
Arm Type
Active Comparator
Arm Description
High-flow nasal oxygen therapy is conducted for the participants during sedation.
Intervention Type
Procedure
Intervention Name(s)
SJOV
Intervention Description
SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
Intervention Type
Procedure
Intervention Name(s)
HFNO
Intervention Description
HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
Primary Outcome Measure Information:
Title
Hypoxia during sedation
Description
An SPO2 of 75 - 89% for < 60 s
Time Frame
During sedation procedure
Secondary Outcome Measure Information:
Title
respiratory-related complications
Description
pulmonary aspiration, respiratory depression (SPO2 = 90-95%) and severe hypoxia (SPO2 < 75% or < 90% for > 60s)
Time Frame
During sedation procedure
Title
cardiovascular-related complications
Description
hypotension (systolic blood pressure < 90 mmHg), hypertension (systolic blood pressure > 160 mmHg), bradycardia (heart rate < 50 beats/min), tachycardia (heart rate > 120 beats/min)
Time Frame
During sedation procedure
Title
fatal complications
Description
severe anaphylactic reactions, myocardial infarction, cardiac arrest and death
Time Frame
from sedation initiation to 20 min after patients are awake
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18 years or older;
underwent routine gastrointestinal endoscopy under procedural sedation;
consented to participate in this trial.
Exclusion Criteria:
infection of the upper airway;
anatomical abnormalities of the face, nose, and upper airway;
coagulopathies;
anticipated or known difficult airway;
known allergy against propofol, soybeans, and egg;
absence from the high-altitude environment during the past 3 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bailin Jiang
Phone
86-13810986114
Email
jiangbailin@bjmu.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Ciren Laba
Phone
86-13989098788
Email
lbcr010203@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yi Feng
Organizational Affiliation
Peking University People's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tibet autonomous region people's hospital
City
Lhasa
State/Province
Tibet
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ciren Laba
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes
We'll reach out to this number within 24 hrs